Supporting Text S1
A) HRV1A was pre-treated without (left panel) or with niclosamide (right panel)
in infection medium at 37°C for 30 min, diluted 10-fold into infection medium, added to cells for 7 h followed by infection analyses as described in materials and methods. Cells inoculated with virus, which was not pretreated with niclosamide were treated with drug concentrations corresponding to the concentrations from the pre-treated viruses. Note that there was no difference in the infection profile from viruses pre-treated or not with niclosamide.
B) Infection profiles from HRV1A, 2, 16 and CVB3 pre-treated or not with different concentrations of niclosamide. The experiment was carried out as described in panel a) with the addition that data were normalized to the respective untreated infection control in order to allow easier comparison between different viruses. The data show closely overlapping inhibition curves independent of whether the viruses were pre-treated with the drug or not. 10 -4 10 -3 10 -2 10 -1 10 0 virus (µl) 10 -4 10 -3 10 -2 10 -1 10 0 virus (µl) 10 -4 10 -3 10 -2 10 -1 10 0 virus (µl) 10 -4 10 -3 10 -2 10 -1 10 0 virus (µl) 10 -4 10 -3 10 -2 10 -1 10 0 virus (µl) 
